AbbVie has treated the first subject in the Phase III CERVINO clinical trial of its investigational product ABBV-383 to treat relapsed/refractory multiple myeloma (r/r MM).

ABBV-383 is a bispecific antibody T-cell engager that binds to both BCMA and CD3, designed to target and engage T-cells to fight cancer cells.

The multi-centre, open-label, randomised, global trial is designed to assess ABBV-383 against standard available therapies.

It will enrol 380 adult patients with r/r MM who have received a minimum of two lines of treatment previously, including proteasome inhibitors (PI), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAb).

Those previously treated with BCMA-targeted therapies will not be eligible for the trial.

Trial subjects will be randomised into a 1:1 ratio to receive either ABBV-383 administered intravenously every four weeks or the investigator’s choice of standard available therapy (SAT).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The SAT options include combinations of carfilzomib and dexamethasone, elotuzumab with pomalidomide and dexamethasone, or selinexor with bortezomib and dexamethasone.

The company plans to enrol subjects at nearly 140 sites across the globe.

Progression-free survival and overall response rate are the trial’s dual primary endpoints.

Overall survival, complete response or better, very good partial response or better, the rate of minimum residual disease negativity and changes in disease symptoms and physical functioning comprise secondary endpoints.

AbbVie oncology, haematology therapeutic area head and vice-president Mariana Cota Stirner said: “The start of the CERVINO Phase III trial marks an important step forward in AbbVie’s continued commitment to advance new oncology treatments and elevate the standard of care for blood cancer patients.

“ABBV-383 is being evaluated with monthly dosing from the beginning of treatment, with the goal of maximising treatment simplicity for physicians and patients, if proven in the clinical trials.”

In April, the company reported positive top-line data from the first period of the Phase III SELECT-GCA study of upadacitinib plus a steroid taper regimen in adults with giant cell arteritis (GCA).